We next determined whether we could measure brevetoxin activity in blood extracted from the card using receptor assay
This Frost & Sullivan research service titled Developments in Cell Based Assays
focuses on the technological advancements, emerging trends, drivers, and challenges affecting the development of cell-based assays
The luminometer was programmed to inject each well with 20 [micro]L of Luciferase Assay
Reagent (Promega, Madison, WI), and read the luminescence generated for 10 sec.
HTG's lysis-only quantitative Nuclease Protection Assay
(qNPA(TM)) platform allows scientists to test any sample while avoiding the need for extraction or target amplification.
A novel ligand assay
for the rapid screening of a large number of compounds has been developed to characterize synthetic and natural PPAR ligands (30).
This Second Edition includes additional content to reflect recent advancements in assay
Forward-looking statements include, but are not limited to: 1) Sentigen's Tango Assay
System and division arrested Assay
Ready Cells will improve Invitrogen's position in assay
development for GPCRs; and 2) the Sentigen business will become a part of Invitrogen's Discovery Sciences Group.
More importantly, RapidQuant IgG kits combine with other Guava assays
to accelerate the entire process of antibody screening by allowing all stages of screening to be performed from the culture media in a single well, typically without having to expand clones.
Enable Researchers to Easily Conduct Experiments Using the Recently Completed HapMap Dataset and Additional Pharmaceutically Relevant 'Coding SNPS'
The PathHunter cell based assay
platform utilizing the ProLabel(TM) tag has proven to be an enabling system for drug discovery that provides a unique assay
platform to measure protein expression, degradation, secretion and translocation for a variety of drug discovery target classes.
Mottley continued: "Stage 1 and 2 assays
on approximately 2,400 feet of drilling has been completed and reported on.
Division Arrested Assay
Ready Cells(TM) are designed to reduce the need of our clients to engage in costly ongoing cell culture operations to support cell-based drug discovery, effectively uncoupling the process of cell production from drug screening.